Xebio Holdings Co., Ltd.
Notice Regarding Grant of Stock-Based Compensation for Directors
Resolved to issue and grant 187 stock-based compensation options to two directors (foreign directors excluded), comprising 18,700 shares of common stock as the target shares, with 100 shares per option. Grant date: 2026/09/15; exercise period: 2026/09/16 to 2056/09/15. Exercise price set at fair value on grant date, rounding down fractions, capital increase capped at half.
Key Figures
- Total number of stock acquisition rights: 187 units
- Target shares: 18,700 shares
- Exercise period: 2026/09/16–2056/09/15
AI要約
Issuance of Stock Acquisition Rights
At today’s Board of Directors meeting, to strengthen the linkage between director remuneration and corporate value, we resolved to募集事項 for stock-based compensation options and decided to grant them. The targets are two directors (excluding external directors), total 187 units, 100 shares per unit, and 18,700 shares of common stock. The exercise period is 2026/09/16–2056/09/15, and the exercise price is the amount obtained by multiplying the fair value on the grant date by 1 yen per share.
Conditions / Adjustments
The exercise of the stock acquisition rights requires payment of the fair value calculated by the Black-Scholes model. There are various adjustments and conditions, including adjustments for stock splits and reverse splits, and capital increase limits capped at half of the increase in capital. Other conditions during the exercise period follow agreements based on resolutions by the shareholders meeting and the Board of Directors.
Xebio Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
